Inspira Technologies Oxy BHN Ltd (IINN)

[81vette]

nhod accumulation @.2159,this is going to explode soon

[81vette]

MMX moving up,1.27 now

[81vette]

accumulation at open .0005 now .20,thats astounding buying and holding!! MMX just moved up to 1.26,lets see what happens if he stays there

[81vette]

bad mm,"MMX"@1.24,thru it and should move up fast to where ever MMX moves up to,hopefully $2 ,bid(demand) growing now so it shouldn't be long,MMX@ bid 1.19 support also

[81vette]

https://www.prnewswire.com/news-releases/inspira-announces-plans-to-launch-and-target-single-use-disposable-blood-oxygenation-kit-for-a-new-disposable-perfusion-market-opportunity-302029857.html

[81vette]

https://www.prnewswire.com/news-releases/inspira-technologies-signs-strategic-agreement-to-enter-gulf-states-with-glo-med-for-deployment-of-531-inspira-art-devices-302047961.html

[81vette]

finally the bounce off sma50(5min) i had bids in for filled 1.17/1.18 support

[81vette]

only 1.24m debt is low for a bio,

[81vette]

23%/12% volatility,eps surprise of 27%6.4m cash(offering dec 28),flipped to bullish 2 days ago,sma200@ 1.27 (blue sky ma res. above) awaiting fda approvals is why it started going up,ppl at fda/insiders/tutes know what is coming,$100's of millions rev. is fueling greed here!

[81vette]

nhod's,med patent approval,tutes transactions up 67%,zb and not optionable,gone up all day (didnt even flinch in death hour)

[peterus]

geez my nose almost gone

[nadodude]

You tell me????? Do your own DD.

Look for the 13-F's. Why----Inspira is working on establish collaborations with strategic partners and globally ranked health centers, to provide endorsement and future clinical adoption of its ART system. In addition, Inspira explores collaborations with leading medical device companies, manufactures, and distributors. The development of a strategic team is key to enable Inspira to rapidly deploy the ART in the future.

[peterus]

were is the clinical proof ????

[nadodude]

Interview with Dagi Ben-Noon, Co-Founder and CEO at Inspira Technologies (Nasdaq: IINN):
Web Link to Interview

I think this is huge as the best option to avoid the Ventilator, which will most likely kill you! Just my thoughts.

Q: Could you provide our readers with a brief introduction to your company?
A: Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. Inspira has a vision- Provide a new innovative way to treat respiratory failure. Every year approx. 20 million patients are admitted to ICUs due to respiratory failure, being intubated, placed in a medically induced coma, and undergo mechanical ventilation. Inspira’s ART system designed to prevent the need for mechanical ventilation (MV), whose disadvantages have become more apparent since the beginning of the COVID-19 pandemic. Inspira develops a cost-effective minimally invasive Extracorporeal Respiratory Support (ECRS) technology, which the company believes has the potential to utilize oxygen to rebalance patients’ saturation levels while they are awake.
Inspira’s ART system, which is based on ECRS technology, acts as external lungs, by withdrawing blood through a dual lumen cannula inserted into the jugular vein, enriching it with a high concentration of oxygen, removing CO2, and returning the enriched blood to rebalance patient’s saturation levels and take the load off the lungs. Inspira’s technology has the potential to prevent the need for mechanical ventilation.

Q: Any highlights on your recent announcement?
A: Inspira completed NASDAQ IPO last month, since than the company appointed a new medical board member to its advisory board, Dr. Dekel Stavi which considerable experience in Extracorporeal Life Support programs, and cardiology aspects of ICU’s patients, and we believe his experience will contribute Inspira in the next development stages. Inspira also announced the introduction of an innovative microbubble platform designed to extend the life of oxygenators products and potentially prevent blood clots when integrated into a treatment regimen.

Q: Can you give us more insights into your offering?
A: Inspira Technologies is now listed on the Nasdaq stock exchange under the ticker symbol “IINN”. The IPO was priced on July 13, 2021, with the official closing scheduled for Friday, July 16, 2021. The gross proceeds of the offering were approximately $16 million before deducting underwriting discounts, commissions, and offering expenses.

Q: What can we expect from your company in the next 6 months? What are your plans?
A: Inspira taking a multi-step approach to bring its ART system to the market. By the end of 2023, Inspira is planning on introduce the ART system to the market with the new intent of use. As we have two parallel paths that are linked, we will initially submit a 510k to one of our components at the end of 2022, and we plan to submit Inspira’s integrated system 510k at the end of that year. As part of Inspira’s strategy to reach this goal, and in parallel to pursuing regulatory approvals, Inspira is working on establish collaborations with strategic partners and globally ranked health centers, to provide endorsement and future clinical adoption of its ART system. In addition, Inspira explores collaborations with leading medical device companies, manufactures, and distributors. The development of a strategic team is key to enable Inspira to rapidly deploy the ART in the future.

Q: What is the best thing about your company that people might not know about?
A: Passionate and professional team with an innovative vision and a track record of success in execution. A highly experienced management team with a proven track record of success. The chairman, Prof. Benad Goldwasser has 10 exits to his name, Dagi Ben-Noon, one of the Co-Founders, is a serial entrepreneur and was one of Nano Dimension (NNDM) Co-Founders. Joe Hayon, the second Co-Founders and the company’s CFO has extensive experience in executing M&As and strategic joint ventures, manufacturing, and operations to support high-growth delivery. The third Co-Founder is Dr. Udi Nussinovitch is the Chief Scientific Officer of the company. Udi is a board-certified Cardiologist, ICU Physician, and Cardiology Researcher, as well as an expert hyperbaric and diving physician.

[maestro_of_Ihub]

Who else sold and bought back today? Netted a bonus 97,000 free shares I didn’t have this morning! See you all at $20 in 2025! I am in Grand Cayman! Probably a good place for next years newly minted millionaire party! 🎉👏🏻

[NinjaGalaxy36]

If anyone wondering why company’s stock is surging now
Inspira Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System
https://finance.yahoo.com/news/inspira-receives-first-ever-u-123000406.html

[powerbattles]

They have pending FDA approval, and with the patent approval, it's even more promising. This stock, for me, is strictly for trading purposes, so I won't delve into deep details. Look like the volume has increased, and hopefully, the short sellers will close their positions before the market closes. If they release their grip, this could potentially push the stock back above the $1.60 mark by the close.
Good luck to you bro.

[Pt3]

Chased 2 now trapped

[Invest-in-America]

IINN: HOPE you are right, Dude. (Little push-UP in price goin' on right now.)

[Invest-in-America]

IINN: Late little run-up here, HOPEFULLY!!

[Invest-in-America]

IINN: But at least you scored some nice BANK; & all your points are well taken. (I hate to say this again, but that word "ISRAEL" does NOT help ANY stock these days, in light of the SLAUGHTER they are doing over there. And I ain't no "ANTI-SEMITE" nonsense.)

[Stijn]

Most trading happened in pre hours and volume has gone down during the day. Lots of algo-trading as well.
But may seem like volume is picking up again right now. This may in fact trade well after hour and tomorrow, as it's not just a P&D (this mornings action sure looks like one), but the upwards move actually has a reason.
Time will tell if it we end at 1 or 2 tomorrow.

[powerbattles]

I purchased IINN 1.23 PM and sold it at 1.97. After checking the filings, I found they only had a 5 million offering, which occurred in Oct, last year. Therefore, I decided to reload again, acquiring 3600 shares at 1.17. It's practically impossible to trade with three times the outstanding shares and no movement whatsoever. This situation is criminal, the system needs to address and fix it.

02/14/24 09:02 AM ET Sell 2400 IINN Executed @ $1.9703

[Invest-in-America]

IINN: Indeed SICK, P-B!!! (But then --- similar to Pharm PR's about mere PRE-Phase-1 drug studies --- peeps may see this as just a garden-variety PATENT routine, with no substance GADETS for years to come; anyway, that's my guess here. I myself got WAY TOO EXCITED behind this kind of "news".)

Maybe near the Close today, I'll recoup SOME of my loses here.

[powerbattles]

Pure manipulation. Unless they turn off their robots, this won't do any good. With an outstanding share count of 11.3 million, it's pathetic that we're not moving higher.

[Invest-in-America]

IINN: BOUNCE!!! You P.O.S. dead-cat stock!!! Or my Daughter --- see her live, below --- will EAT YOU for DINNER!!!

[Invest-in-America]

IINN: Whatchu-talkin'-bout, Willis???!!!

[Tim-tom23]

How much I wrote about her here, only God knows. Finally the announcement we've been waiting for!!!
Where.
Where is the guy who keeps trying to get us off her?!?

[Invest-in-America]

IINN: Let's get goin'!!! (I'm still holdin' your shares, IINN Company!!)

"Why Inspira Technologies (IINN) Stock Is Popping Off
BENZINGA
9:01 AM ET Feb-14-2024
Inspira Technologies Oxy BHN Ltd (IINN.NaE) shares are trading higher by 113.5% to $2.05 Wednesday morning after the company announced the approval of a U.S. Patent for its orbiting blood oxygenation delivery system, VORTX, a component of the INSPIRA ART500 device. Inspira Technologies says this technology is set to disrupt the conventional approach to blood oxygenation by eliminating the need for fiber membranes, thereby minimizing damage to blood cells. CEO Dagi Ben-Noon views this achievement as a pivotal moment in the company’s journey toward enhancing patient care and advancing healthcare technology."

[Invest-in-America]

IINN: The bottom line here?? Let's KICK-ASK now, IINN Company!!!

[Invest-in-America]

IINN: This is now the 'Magic Hour' for Wall Street, generally. If IINN doesn't begin a move UPWARD now, well, not likely that it ever will today, at least. (But I'm still holding all mine.)

PS: If this Firm was headquartered in any place buy ISRAEL, well, its PRICE would already be on the Moon today behind that kind of good news. Bottom line, Israel can NOT be slaughtering 30,000+ of their perceived 'enemies', and then fancy that their firms on Wall Street will do well. "Karma" doesn't work that way. Too bad that I myself did NOT pay enough attention to this sad fact.

[Invest-in-America]

IINN: A little comeback here??

[Invest-in-America]

IINN: Heck, not even a "pop" at all, after the Open. SHOCKING. (Truth be told, Dude, I believe it is that word "ISRAEL" that killed this one.)

[peterus]

yup sick

[madras50]

well that was a quick pop and drop.

[peterus]

out 1.20s

[peterus]

1.25s back in

[Invest-in-America]

IINN: Yep!! (Gonna take awhile, though, for the IMPORTANCE of their news to sink-into the Global Medical Community today, & in the ensuing weeks.)

[peterus]

nice dip 1.50s
lets break 2s today before we see approval in the next few weeks

[Invest-in-America]

IINN: Good MORN, King P-B!!! WOW!!! We gots at least a 5-bagger here, Dude (IMO)!! I saw your's & Lord Peterus's posts on this --- THANKS to both of you!!! And, I saw it too on Benzinga's list. I'm posting the actual LINK to the PR across iHub so others can read it for themselves.
https://www.prnewswire.com/news-releases/inspira-receives-first-ever-us-patent-approval-for-an-orbiting-blood-oxygenation-delivery-system-302061765.html#:~:text=(Nasdaq%3A%20IINN)%20(Nasdaq,the%20revolutionary%20INSPIRA%E2%84%A2%20ART500

[subslover]

Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System
94% of the Claims Were Found to be Novel

RA'ANANA, Israel, Feb. 14, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), is a breakthrough medical technology company targeting to supersede mechanical ventilators, has received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the revolutionary INSPIRA™ ART500 device. This innovation has 16 claims found to be novel.



https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg


The orbiting blood oxygenation delivery system (VORTX™) is designed to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical landscape. The current fiber technologies used for blood oxygenation cause substantial damage to the patient's blood cells. Unlike the natural laminar blood flow in blood vessels inside the body, in existing fiber oxygenators, the blood is "forced" to flow in a harmful turbulent flow through many layers of fibers while experiencing friction and shear forces within the fiber walls. Since the fiber fabric is a significant resistor to blood flow, high-pressure differences are formed and cause significant damage to the various blood components, including, high hemolysis (breakdown of red cells), damage to white blood cells, activation of the inflammatory system in the body, activation of the immune system, and blood clotting.

We believe that the orbiting blood oxygenation delivery system is another potentially game-changing core technology of the INSPIRA ART500 device, in targeting the $19 billion mechanical ventilation market.

The INSPIRA ART500 is a breakthrough device, designed to empower breathing in patients that are awake, by continuously measuring the patient's blood parameters in real-time, and delivering needed oxygen volume straight into the blood. As the INSPIRA ART500 is to be equipped with the HYLA blood sensor, it is being designed to continuously scan the patient's blood, potentially allowing for real-time detection of changes in patient condition and providing physicians with decision-supportive data.

CEO of Inspira Technologies Dagi Ben-Noon: "We believe that this is a monumental advancement in the landscape of blood oxygenation technologies and a pivotal milestone and another key indicator of the INSPIRA ART500's core technological portfolio."

Inspira Technologies OXY B.H.N. Ltd.

Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity. For more information, please visit our corporate website: https://inspira-technologies.com.

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses intended benefits and uses of its technology, that its technology has the potential to revolutionize the medical landscape, the target market for its product, the potential of its products to allow for real-time detection and the belief that the patent approval is a monumental advancement in the landscape of blood oxygenation technologies. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www.sec.gov.

[powerbattles]

Fully loaded 1.43 This could go wild.

[Invest-in-America]

IINN: A MONSTER runner here, Admiral Pete, Sir!!!! (As if you didn't already know!! Just kidding!!)

[Invest-in-America]

IINN: Big news --- US Patent, new (non-destructive) way to oxygenate BLOOD.

"Inspira(TM) Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System"

[peterus]

nice news on patent next 510k approval

[NinjaGalaxy36]

$IINN Inspira(TM) Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA(TM) ART Device

https://stockhouse.com/news/press-releases/2024/02/08/inspira-tm-technologies-collaborates-with-a-leading-israeli-medical-center-for

[peterus]

it takes 6 months or 185 days to get approval (510)k could come sooner

[Tim-tom23]

That *

[Tim-tom23]

Can you explain what do you mean by?

[NinjaGalaxy36]

Inspira said in pr in 9.23 that approval will come in next 6 months.